<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04400877</url>
  </required_header>
  <id_info>
    <org_study_id>SE2020-02701</org_study_id>
    <nct_id>NCT04400877</nct_id>
  </id_info>
  <brief_title>Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic</brief_title>
  <official_title>Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the prevalence of venous thromboembolism in a&#xD;
      regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2&#xD;
      pandemic. In a retrospective observational study, we will review patient data, diagnostic&#xD;
      data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic.&#xD;
      This data will be compared with data from the corresponding time frame during the years 2015&#xD;
      to 2019.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current SARS-COV-2 pandemic there is a concern about an increased risk of venous&#xD;
      thromboembolism (VTE) concurrent with the infection, including both pulmonary embolism (PE)&#xD;
      and deep venous thrombosis (DVT) (Klok et al. 2020; Cui et al. 2020; Helms et al. 2020;&#xD;
      Leonard-Lorant et al. 2020; Poissy et al. 2020). International guidelines now recommend&#xD;
      prophylactic anticoagulation for all hospitalized patients with a SARS-COV-2 infection in the&#xD;
      absence of any contraindication (Thachil et al. 2020). The majority of the studies on VTE in&#xD;
      SARS-COV-2 infections have been carried out in the ICU and show prevalence of VTE of between&#xD;
      20 and 30%.(Klok et al. 2020; Cui et al. 2020; Helms et al. 2020). This is a clear increase&#xD;
      compared to the less than 10 % prevalence seen in other ICU patients (Muscedere, Heyland, and&#xD;
      Cook 2007; Deborah Cook et al. 2005; D. Cook et al. 2000). However, a single center study on&#xD;
      consecutive ICU patients with severe sepsis showed a prevalence of VTE of 37% (Kaplan et al.&#xD;
      2015) and another recent publication of patients with severe influenza A/H1N1 infection had a&#xD;
      prevalence of VTE of 44% (Obi et al. 2019).&#xD;
&#xD;
      This raises the question whether the increase in VTE seen in recent publications of&#xD;
      SARS-COV-2 infections is the result of the specific pathophysiology of the virus itself or&#xD;
      the subsequent sepsis with multiorgan failure seen in most complicated and severe cases. The&#xD;
      former would have large implications for patients treated outside the ICU and possibly&#xD;
      outside hospitals (Thachil et al. 2020).&#xD;
&#xD;
      The aim of this study will be to investigate the prevalence of VTE in a regional healthcare&#xD;
      system prior to, and during the SARS-COV-2 pandemic and the differences between ICU,&#xD;
      hospitalized and outpatient cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?</measure>
    <time_frame>March to May in 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?</measure>
    <time_frame>March to May in 2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?</measure>
    <time_frame>March to May in 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?</measure>
    <time_frame>March to May in 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?</measure>
    <time_frame>March to May in 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?</measure>
    <time_frame>March to May in 2020</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">7795</enrollment>
  <condition>COVID-19</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 pos</arm_group_label>
    <description>Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 neg</arm_group_label>
    <description>Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic examination for venous thromboembolism</intervention_name>
    <description>Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.</description>
    <arm_group_label>SARS-CoV-2 neg</arm_group_label>
    <arm_group_label>SARS-CoV-2 pos</arm_group_label>
    <other_name>CT Pulmonary Angiogram (CTPA)</other_name>
    <other_name>Ultrasound for deep venous thrombosis (DVT)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        For enrolment, we will consider all patients who have done a diagnostic examination for&#xD;
        suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system&#xD;
        of Region Östergötland during March, April and May 2015 through 2020. We will also include&#xD;
        all patients with a new diagnosis of pulmonary embolism or deep venous thrombosis during&#xD;
        the same time periods.&#xD;
&#xD;
        Region Östergötland/Östergötland County has a population of 465,495 (December 31, 2019).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient that has done a Computer Tomography Angiography of the lungs between 1:st&#xD;
             of March and 31:st of May each year from 2015 to 2020&#xD;
&#xD;
          -  Any patient that has done a Ultrasound of the legs between 1:st of March and 31:st of&#xD;
             May each year from 2015 to 2020&#xD;
&#xD;
          -  Any patient with a new diagnosis of pulmonary embolism or deep venous thrombosis&#xD;
             between 1:st of March and 31:st of May each year from 2015 to 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete diagnostic examination&#xD;
&#xD;
          -  Follow-up examination of know acute VTE&#xD;
&#xD;
          -  Primary investigation done outside the healthcare system&#xD;
&#xD;
          -  Patient &lt;18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jens Wretborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Department, University Hospital Linköping, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrik Benjaminsson Nyberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Department, University Hospital Linköping, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Jörg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Department, University Hospital Linköping, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://docs.google.com/document/d/1rNUhsHak2dVSHrG0Hz6bV7TVgcdyNc6hGXjrhCOx7HU/edit?usp=sharing</url>
    <description>Complete study protocol as used for approval at the Swedish Ethical Review Authority</description>
  </link>
  <reference>
    <citation>Cook D, Attia J, Weaver B, McDonald E, Meade M, Crowther M. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care. 2000 Dec;15(4):127-32. doi: 10.1053/jcrc.2000.19224.</citation>
    <PMID>11138871</PMID>
  </reference>
  <reference>
    <citation>Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005 Jul;33(7):1565-71. doi: 10.1097/01.ccm.0000171207.95319.b2.</citation>
    <PMID>16003063</PMID>
  </reference>
  <reference>
    <citation>Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.</citation>
    <PMID>32271988</PMID>
  </reference>
  <reference>
    <citation>Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Angles-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.</citation>
    <PMID>32367170</PMID>
  </reference>
  <reference>
    <citation>Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015 Nov;148(5):1224-1230. doi: 10.1378/chest.15-0287.</citation>
    <PMID>26111103</PMID>
  </reference>
  <reference>
    <citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.</citation>
    <PMID>32291094</PMID>
  </reference>
  <reference>
    <citation>Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, Schneider F, Labani A, Bilbault P, Moliere S, Leyendecker P, Roy C, Ohana M. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020 Sep;296(3):E189-E191. doi: 10.1148/radiol.2020201561. Epub 2020 Apr 23.</citation>
    <PMID>32324102</PMID>
  </reference>
  <reference>
    <citation>Muscedere JG, Heyland DK, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. J Crit Care. 2007 Dec;22(4):285-9. doi: 10.1016/j.jcrc.2007.02.003. Epub 2007 Jul 5.</citation>
    <PMID>18086398</PMID>
  </reference>
  <reference>
    <citation>Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S; Lille ICU Haemostasis COVID-19 Group. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24. No abstract available.</citation>
    <PMID>32330083</PMID>
  </reference>
  <reference>
    <citation>Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27. No abstract available.</citation>
    <PMID>32338827</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Daniel Wilhelms</investigator_full_name>
    <investigator_title>MD, Emergency department head of research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04400877
org study id: SE2020-02701
nct id: NCT04400877
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The purpose of this study is to investigate the prevalence of venous thromboembolism in a
      regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2
      pandemic. In a retrospective observational study, we will review patient data, diagnostic
      data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic.
      This data will be compared with data from the corresponding time frame during the years 2015
      to 2019.
In the current SARS-COV-2 pandemic there is a concern about an increased risk of venous
      thromboembolism (VTE) concurrent with the infection, including both pulmonary embolism (PE)
      and deep venous thrombosis (DVT) (Klok et al. 2020; Cui et al. 2020; Helms et al. 2020;
      Leonard-Lorant et al. 2020; Poissy et al. 2020). International guidelines now recommend
      prophylactic anticoagulation for all hospitalized patients with a SARS-COV-2 infection in the
      absence of any contraindication (Thachil et al. 2020). The majority of the studies on VTE in
      SARS-COV-2 infections have been carried out in the ICU and show prevalence of VTE of between
      20 and 30%.(Klok et al. 2020; Cui et al. 2020; Helms et al. 2020). This is a clear increase
      compared to the less than 10 % prevalence seen in other ICU patients (Muscedere, Heyland, and
      Cook 2007; Deborah Cook et al. 2005; D. Cook et al. 2000). However, a single center study on
      consecutive ICU patients with severe sepsis showed a prevalence of VTE of 37% (Kaplan et al.
      2015) and another recent publication of patients with severe influenza A/H1N1 infection had a
      prevalence of VTE of 44% (Obi et al. 2019).

      This raises the question whether the increase in VTE seen in recent publications of
      SARS-COV-2 infections is the result of the specific pathophysiology of the virus itself or
      the subsequent sepsis with multiorgan failure seen in most complicated and severe cases. The
      former would have large implications for patients treated outside the ICU and possibly
      outside hospitals (Thachil et al. 2020).

      The aim of this study will be to investigate the prevalence of VTE in a regional healthcare
      system prior to, and during the SARS-COV-2 pandemic and the differences between ICU,
      hospitalized and outpatient cohorts.
observational model: Cohort
time perspective: Retrospective
measure: Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?
time frame: March to May in 2020
measure: Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?
time frame: March to May in 2020
measure: Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system?
time frame: March to May in 2020
measure: Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities?
time frame: March to May in 2020
measure: How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism?
time frame: March to May in 2020
measure: Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival?
time frame: March to May in 2020
arm group label: SARS-CoV-2 pos
description: Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
arm group label: SARS-CoV-2 neg
description: Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
intervention type: Diagnostic Test
intervention name: Diagnostic examination for venous thromboembolism
description: Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
arm group label: SARS-CoV-2 neg
arm group label: SARS-CoV-2 pos
other name: CT Pulmonary Angiogram (CTPA)
other name: Ultrasound for deep venous thrombosis (DVT)
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
last name: Jens Wretborn, MD
role: Principal Investigator
affiliation: Emergency Department, University Hospital Linköping, Sweden
last name: Patrik Benjaminsson Nyberg, PhD
role: Principal Investigator
affiliation: Emergency Department, University Hospital Linköping, Sweden
last name: Matthias Jörg, MD
role: Principal Investigator
affiliation: Emergency Department, University Hospital Linköping, Sweden
facility: 
country: Sweden
url: https://docs.google.com/document/d/1rNUhsHak2dVSHrG0Hz6bV7TVgcdyNc6hGXjrhCOx7HU/edit?usp=sharing
description: Complete study protocol as used for approval at the Swedish Ethical Review Authority
citation: Cook D, Attia J, Weaver B, McDonald E, Meade M, Crowther M. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care. 2000 Dec;15(4):127-32. doi: 10.1053/jcrc.2000.19224.
PMID: 11138871
citation: Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005 Jul;33(7):1565-71. doi: 10.1097/01.ccm.0000171207.95319.b2.
PMID: 16003063
citation: Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
PMID: 32271988
citation: Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Angles-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
PMID: 32367170
citation: Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015 Nov;148(5):1224-1230. doi: 10.1378/chest.15-0287.
PMID: 26111103
citation: Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
PMID: 32291094
citation: Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, Schneider F, Labani A, Bilbault P, Moliere S, Leyendecker P, Roy C, Ohana M. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020 Sep;296(3):E189-E191. doi: 10.1148/radiol.2020201561. Epub 2020 Apr 23.
PMID: 32324102
citation: Muscedere JG, Heyland DK, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. J Crit Care. 2007 Dec;22(4):285-9. doi: 10.1016/j.jcrc.2007.02.003. Epub 2007 Jul 5.
PMID: 18086398
citation: Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S; Lille ICU Haemostasis COVID-19 Group. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24. No abstract available.
PMID: 32330083
citation: Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27. No abstract available.
PMID: 32338827
responsible party type: Principal Investigator
investigator affiliation: University Hospital, Linkoeping
investigator full name: Daniel Wilhelms
investigator title: MD, Emergency department head of research
mesh term: COVID-19
mesh term: Pulmonary Embolism
mesh term: Thrombosis
mesh term: Embolism
mesh term: Thromboembolism
mesh term: Venous Thromboembolism
mesh term: Venous Thrombosis
sharing ipd: Undecided